Toxicity of radiotherapy combined with immunotherapy for non-small cell lung cancer
10.3760/cma.j.cn113030-20211223-00504
- VernacularTitle:非小细胞肺癌胸部放疗联合免疫治疗的不良反应特点
- Author:
Tongzhen XU
1
;
Jun LIANG
Author Information
1. 国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院北京协和医学院肿瘤医院放疗科，北京 100021
- Keywords:
Carcinoma, non-small-cell lung;
Radiotherapy;
Immunotherapy;
Toxicity;
Pneumonitis
- From:
Chinese Journal of Radiation Oncology
2022;31(11):1059-1064
- CountryChina
- Language:Chinese
-
Abstract:
Radiotherapy combined with immunotherapy for non-small cell lung cancer (NSCLC), especially with PD-1/PD-L1 immune checkpoint inhibitors, have fallen under the spotlight in recent years. However, the combination therapy not only brings potential benefits to patients, but also alters the incidence of adverse events. At present, there is no adequate data to elucidate the incidence of adverse events in all-stage NSCLC patients. In this article, research progress on the toxicities of radiotherapy combined with immunotherapy for various stages of NSCLC, especially pneumonitis, was reviewed, aiming to maximize the benefits for patients with all-stage NSCLC.
